NASDAQ · INCY
Incyte Corporation
$116.80$0.00 (0.0%)
Incyte Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.92% below the high.
Loading market information…
SHH · 600276.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 03:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.52% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Jiangsu Hengrui Medicine Co., Ltd.’s forward annual dividend is CN¥0.20 per share, paid annual. The forward yield is 0.41% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Jiangsu Hengrui Medicine Co., Ltd.’s next earnings report is currently expected on Apr 19, 2027, with estimated earnings per share of CN¥0.32. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jiangsu Hengrui Medicine Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:14 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| CN¥7.43B-16.4% vs estimate |
| Q2 2025 | Aug 20, 2025 | CN¥0.40+27.01% vs estimate | CN¥8.56B-2.83% vs estimate |
|---|
| Q1 2025 | May 30, 2025 | CN¥0.29-0.85% vs estimate | CN¥7.21B+0.85% vs estimate |
|---|
| Q3 2024 | Dec 31, 2024 | CN¥0.27+28.9% vs estimate | CN¥7.80B+22.54% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$116.80$0.00 (0.0%)
Incyte Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.92% below the high.